INHBA promotes the progression of gastric cancer by activating MAPK signaling pathway via targeting ITGA6

Gastric cancer (GC) is one of the most common malignancies, ranking as the fifth most common cancer and the fourth leading cause among cancer related deaths worldwide. Upregulated INHBA expression in gastric cancer tissues compared to adjacent non-cancerous tissues was confirmed by immunohistochemistry and qRT-PCR analysis. This increased expression of INHBA was found to be significantly associated with the incidence of tumor lesion, lymph node metastasis and the progression to more advanced TNM stages in patients. Functional experiments showed that INHBA could promote the proliferation of GC cells, enhance migration and invasion in vitro, while simultaneously facilitating the inhibition of apoptosis. To test whether INHBA regulated the tumor growth in vivo, the animal studies were performed. The indicated that INHBA over-expression promoted the tumor growth, including weight and volume. Moreover, this study demonstrated through a series of experiments including RNA-seq, Co-IP, Co-IF, Western blot, and Rescue studies that INHBA promotes the progression of GC by targeting ITGA6 to regulate the MAPK signaling pathway. In summary, understanding the role of INHBA/ITGA6/MAPK in tumourigenesis could provide new insights into gastric cancer therapy and targeted inhibition of INHBA might be a potential therapeutic approach for GC treatment.